Literature DB >> 7922399

Nosocomial infections in intensive care units: an overview of their epidemiology, outcome, and prevention.

M A Martin1.   

Abstract

Among all hospitalized patients, ICU patients are at greatest risk for both endemic and epidemic nosocomial infections. The highest infection rates are seen in surgical, burn, trauma, and neonatal ICUs. Acquisition of infection is a major determinant of mortality in ICUs, and prolongs the length of ICU stay. Predominant pathogens include Pseudomonas aeruginosa, Enterobacter cloacae, Staphylococcus aureus, enterococci, and Candida spp. They are more likely to be resistant to antimicrobial agents than are isolates from elsewhere in the hospital. Exposure to invasive medical devices is the predominant risk factor for infection, and strategies to prevent infection are aimed at reducing microbial colonization on and around devices. Improvements in technology, such as coating devices with antimicrobial agents, have been shown to be efficacious in preventing infection. Handwashing, particularly with antiseptic soaps, remains the cornerstone of infection control in the ICU.

Entities:  

Mesh:

Year:  1993        PMID: 7922399

Source DB:  PubMed          Journal:  New Horiz        ISSN: 1063-7389


  3 in total

1.  Candidemia in intensive care unit patients: risk factors for mortality.

Authors:  A Voss; J L le Noble; F M Verduyn Lunel; N A Foudraine; J F Meis
Journal:  Infection       Date:  1997 Jan-Feb       Impact factor: 3.553

2.  Deficiency of mannose-binding lectin greatly increases susceptibility to postburn infection with Pseudomonas aeruginosa.

Authors:  Mette Møller-Kristensen; W K Eddie Ip; Lei Shi; Lakshmi D Gowda; Michael R Hamblin; Steffen Thiel; Jens Chr Jensenius; R Alan B Ezekowitz; Kazue Takahashi
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

3.  Highly drug-resistant pathogens implicated in burn-associated bacteremia in an Iraqi burn care unit.

Authors:  Jean-Baptiste Ronat; Jabar Kakol; Marwan N Khoury; Mathilde Berthelot; Oliver Yun; Vincent Brown; Richard A Murphy
Journal:  PLoS One       Date:  2014-08-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.